By Fisentzos Stylianou, PhD Contact: [email protected] NICE’s launches a real-world evidence framework Closing knowledge gaps and advancing patient access to innovations are major aims of the
London, United Kingdom, April 27, 2022- Leading specialist market access consultancy Partners4Access analyst’s have been awarded ‘Highly Commended’’ Analyst Team of the Year 2022 by
By Fisentzos Stylianou, PhD Contact: [email protected] One of the main healthcare challenges raised by the European Medicines Agency’s (EMA) network strategy to 2025 is the
By Chloe Sheppard, Associate Consultant Contact: [email protected] A major milestone in the creation of pan-European joint health technology assessment (HTA) was reached in January this
By Fisentzos Stylianou, PhD Contact: [email protected] In November 2021, Novartis’ Adakveo (crizanlizumab) became the first treatment for sickle cell disease (SCD) to be made available
By Andrea Bernardini, Senior Analyst Email: [email protected] AIFA has approved reimbursement of the orphan drug Evrysdi (risdiplam) by Roche, the first at-home oral treatment for Spinal
By Andrea Bernardini, Senior Analyst Email: [email protected] Intensifying pressure to implement cost savings due to COVID induced economic downturn and the current ruling coalition, seem
By Andrea Bernardini, Senior Analyst Email: [email protected] The latest approved Budget Law for the three-year period 2022-2024 is quite extensive and covers the whole planned spending
By Andrea Bernardini, Analyst & Akshay Kumar, Partner Email: [email protected] [email protected] On the 12th of February the Orphan Drugs Observatory and the Italian Society of
